NeuroAdjuvants

NeuroAdjuvants is a preclinical-stage biotechnology company focused on developing systemically active, blood-brain barrier-penetrating neuropeptide-based therapeutics. Founded in 2005 as a spin-off from the University of Utah, the company's research centers on engineering metabolically stable galanin receptor agonists to treat neurological and psychiatric disorders, including refractory epilepsy and chronic pain. Its lead preclinical candidates include NAX 810-2, a GalR2-preferring agonist for epilepsy, and NAX 409-9, a peripherally acting GalR2 agonist designed for pain management without central side effects. Although the company has ceased active operations, its patented neuropeptide technologies and research collaborations have significantly contributed to the field of neurostabilizing peptide drug discovery.